Drugs / TUB-030
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06657222 | Dec 2024 → Dec 2028 expected | head and neck squamous cell carcinoma, non-small cell lung carcinoma, small cell lung carcinoma, triple-negative breast carcinoma | Tubulis GmbH | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-04-08 | Tubulis GmbH | Results Tubulis Presents Preclinical Data for Solid Tumor Targeting ADC Candidates TUB-030 and TUB-040 Demonstrating Superior Efficacy Profile and a Wide Therapeutic Window at the AACR Annual Meeting 2024 tubulis.com ↗
The poster presentations contained preclinical data, highlighting the ability of the two next-generation Tubutecan ADCs to create effective and durable responses even in low target-expressing tumor mouse models. |
All press releases naming this drug 2 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TUB-030 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06657222 ↗ |
| Modality | Other / unclassified | “the 5T4 ADC TUB-030” NCT06657222 ↗ |
| Route | Intravenous | “TUB-030 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle” NCT06657222 ↗ |